secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-091130
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Pharma Q2 net loss $4.3M; cash only into Q4 2023; ELX-02 positive biopsy data
--------------------------------------------------------------------------------

- Net loss of $4.3M ($1.96 EPS) vs $10.6M ($4.90 EPS) in prior-year quarter.
- Cash $4.3M at June 30; raised $1.7M gross via ATM program post-quarter.
- All 3 patients on ELX-02 showed improved podocyte foot process effacement in kidney biopsies; company plans pivotal Alport trial pending funding.
- FDA cleared IND for ZKN-013 SAD study in RDEB; first dosing expected by end 2023.
- Nasdaq extended compliance deadline for $35M market value listing rule to October 9, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923091130/0001104659-23-091130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923091130/tm2323659d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-091130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer